2-(methylsulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]-pyridin-3-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(methylsulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]-pyridin-3-amine
• 英文别名: 2-(methylsulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]pyridin-3-amine；US9790233, ID SW208079；2-methylsulfinyl-4-phenyl-6-thiophen-2-ylthieno[2,3-b]pyridin-3-amine
• 化学式: C₁₈H₁₄N₂OS₃
• 分子量: 370.52
• InChiKey: BCCLLEGQIPOMJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  132
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-phenyl-6-(thiophen-2-yl)-2-thioxo-1,2-dihydropyridine-3-carbonitrile 在 三乙胺 、 potassium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 0.83h， 生成 2-(methylsulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]-pyridin-3-amine
  参考文献：
  名称：

  Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair

  摘要：

  The enzyme 15-prostaglandin dehydrogenase (15-PGDH) catalyzes the first step in the degradation of prostaglandins including PGE2. It is a negative regulator of tissue repair and regeneration in multiple organs. Accordingly, inhibitors of 15-PGDH are anticipated to elevate in vivo levels of PGE2 and to promote healing and tissue regeneration. The small molecule SW033291 (1) inhibits 15-PGDH with K-i = 0.1 nM in vitro, doubles PGE2 levels in vivo, and shows efficacy in mouse models of recovery from bone marrow transplantation, ulcerative colitis, and partial hepatectomy. Here we describe optimized variants of 1 with improved solubility, druglike properties, and in vivo activity.

  DOI：

  10.1021/acs.jmedchem.7b00271

文献信息

• [EN] COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE LA DÉSHYDROGÉNASE À CHAÎNE COURTE
  申请人：UNIV CASE WESTERN RESERVE

  公开号：WO2015065716A1

  公开（公告）日：2015-05-07

  Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

  调节15-PGDH活性的化合物和方法，调节组织前列腺素水平，治疗希望调节15-PGDH活性和/或前列腺素水平的疾病、疾病障碍或病况，包括本文所描述的15-PGDH抑制剂。
• [EN] INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS<br/>[FR] INHIBITEURS DE L'ACTIVITÉ DE LA DÉSHYDROGÉNASE À CHAÎNE COURTE POUR LE TRAITEMENT DE LA FIBROSE
  申请人：UNIV CASE WESTERN RESERVE

  公开号：WO2016144958A1

  公开（公告）日：2016-09-15

  A method of treating or preventing a fibrotic disease, disorder or condition includes administering to a subject in need of treatment a 15-PGDH inhibitor.

  治疗或预防纤维化疾病、紊乱或状况的方法包括向需要治疗的对象施用15-PGDH抑制剂。
• [EN] COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY<br/>[FR] COMPOSITIONS ET MÉTHODES POUR MODULER L'ACTIVITÉ 15-PGDH
  申请人：UNIV CASE WESTERN RESERVE

  公开号：WO2013158649A1

  公开（公告）日：2013-10-24

  Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.

  调节15-PGDH活性的化合物和方法，调节组织前列腺素水平，治疗疾病、疾病障碍或状况，其中希望调节15-PGDH活性和/或前列腺素水平的包括本文所述的15-PGDH抑制剂和15-PGDH激活剂。
• COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY
  申请人：Case Western Reserve University

  公开号：US20150072998A1

  公开（公告）日：2015-03-12

  Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.

  本发明涉及化合物和调节15-PGDH活性的方法，调节组织前列腺素水平，治疗疾病、疾病障碍或条件，其中希望调节15-PGDH活性和/或前列腺素水平的方法包括本文所述的15-PGDH抑制剂和15-PGDH激活剂。
• Compositions and methods of modulating 15-PGDH activity
  申请人：CASE WESTERN RESERVE UNIVERSITY

  公开号：US10301320B2

  公开（公告）日：2019-05-28

  Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.

  调节 15-PGDH 活性、调节组织前列腺素水平、治疗疾病、疾病紊乱或希望调节 15-PGDH 活性和/或前列腺素水平的情况的化合物和方法包括本文所述的 15-PGDH 抑制剂和 15-PGDH 激活剂。